Innovative Biologics, Inc.

Contact: Jeff Conroy, CEO **Location:** Herndon, Virginia

Email: ixc@innovbio.com

Tel: 703.346.0751





National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile


Industry Sector: Medical Devices

Company Overview: IBI is developing a drug which blocks pore-forming toxins, specifically a-toxin, a key virulence factor of MRSA.


- Secured \$1.8 million NIH grant funding
- \$200,000 from CIT BioLife Fund and Johnson & Johnson
- USAMRIID Anthrax collaboration
- Method and pharmaceutical composition patents

Target Market(s): Methicillin-resistant Staphylococcus aureus Infection (MRSA.

- 20, 0000 deaths in the US from MRSA in 2008
- Will become the third leading cause of death in the US within 5 years.
- 85% of MRSA Infections are acquired in the hospital.
- Everyone is at risk.



Development Timeline



Investment Summary

Investment Summary:

- \$2 million 2 candidates patents leading edge science
- Know what we have to do to achieve objectives
- Executing faster and cheaper
- Seeking Series A financing of \$5 to \$7 million
- Exit transaction with pharma partner in 24 to 36 months